{
    "thread": {
        "uuid": "779b07c68411ec6ffe2e72ec7606f21861b42611",
        "url": "https://www.gurufocus.com/news/2798673/xilio-therapeutics-to-present-updated-phase-2-data-for-vilastobart-a-tumoractivated-fcenhanced-antictla4-in-combination-with-atezolizumab-in-patients-with-microsatellite-stable-colorectal-cance",
        "site_full": "www.gurufocus.com",
        "site": "gurufocus.com",
        "site_section": "https://www.gurufocus.com/rss.php",
        "site_categories": [
            "investing",
            "financial_news",
            "finance"
        ],
        "section_title": "GuruFocus New Articles",
        "site_title": "GuruFocus | Stock Market Research, Data and Tools",
        "title": "Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, ...",
        "title_full": "Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, ...",
        "published": "2025-04-24T00:07:11.248+03:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
        "performance_score": 0,
        "domain_rank": 8416,
        "domain_rank_updated": "2025-04-22T00:00:00.000+03:00",
        "licensing_agency": [],
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "779b07c68411ec6ffe2e72ec7606f21861b42611",
    "url": "https://www.gurufocus.com/news/2798673/xilio-therapeutics-to-present-updated-phase-2-data-for-vilastobart-a-tumoractivated-fcenhanced-antictla4-in-combination-with-atezolizumab-in-patients-with-microsatellite-stable-colorectal-cance",
    "ord_in_thread": 0,
    "author": "@gurufocus",
    "published": "2025-04-24T00:07:11.248+03:00",
    "title": "Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, ...",
    "text": "- Xilio Therapeutics (\nXLO,Financial) to present updated Phase 2 data for vilastobart at ASCO 2025. - The trial investigates a combination therapy for metastatic microsatellite stable colorectal cancer (MSS CRC).\n- Data presentation scheduled for May 31, 2025, in Chicago, Illinois.\nXilio Therapeutics, Inc. (XLO) has announced its plan to present updated data from its ongoing Phase 2 clinical trial for vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody. This presentation is part of the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.\nThe focus of this trial is the efficacy of vilastobart when used in combination with atezolizumab (TecentriqÂ®) in patients suffering from metastatic microsatellite stable colorectal cancer (MSS CRC). The presentation detailing these findings is scheduled for Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT, during the Gastrointestinal Cancer - Colorectal and Anal poster session.\nThe Abstract ID for this presentation is 3553, and it will be displayed on Poster Board 222 at the conference. This event is expected to offer significant insights into the potential benefits and advancements of the vilastobart-atezolizumab combination therapy, as Xilio continues to explore novel approaches to cancer treatment.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Health",
        "Science and Technology"
    ],
    "topics": [
        "Health->cancer",
        "Health->medical profession",
        "Health->health treatment and procedure",
        "Science and Technology->biotechnology",
        "Science and Technology->scientific publication",
        "Science and Technology->medical research"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": false,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
        "persons": [],
        "locations": [],
        "organizations": [
            {
                "name": "ASCO",
                "sentiment": "negative",
                "tickers": []
            },
            {
                "name": "Xilio Therapeutics, Inc.",
                "sentiment": "none",
                "tickers": []
            }
        ]
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "trust": {
        "categories": [],
        "bias": null,
        "source": {
            "type": null,
            "city": null,
            "state": null,
            "country": null,
            "domain_type": null,
            "agency": null,
            "organization_name": null
        }
    },
    "rating": null,
    "crawled": "2025-04-24T00:07:11.248+03:00",
    "updated": "2025-04-24T00:07:11.248+03:00"
}